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Let Common Sense Prevail in Medical Decision Making*Khurram Nasir, MD, MPHW ithin the wider context of health caredelivery sciences, the focus on medicaldecision making is a fairly recent occur-
rence. Dr. Lee Lusted (1), a pioneer in medical deci-
sion analytics, published the ﬁrst major article
emphasizing this theme in 1971. A few years later,
New England Journal of Medicine (2) followed suit,
by dedicating an entire issue to emerging concepts
around decision making in medicine. In a classic
1976 editorial, “Is decision analysis useful in clinical
medicine?” Ransohoff and Feinstein (3) questioned
“Will decision analysis prove to be useful in clinic
medicine? Is it worthwhile to learn about this new
ﬁeld?” During the 1970s, I reckon they probably could
not predict how rapidly this concept would penetrate
medical literature and particularly inﬂuence cardio-
vascular medicine. Over the next 3 decades, hardly
any other topic has received as much attention as
risk modeling to facilitate decision making for accu-
rate prediction of the presence and severity of coro-
nary artery disease (CAD).
In 1979, Diamond and Forrester (4) recommended
principles of decision analysis by presenting a simple,
classic model that considers age, sex, and type of
chest pain to determine the likelihood of obstruc-
tive CAD guiding downstream management. Subse-
quently, multiple other risk scores were formulated*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
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disclose.accounting for additional risk factors, such as dysli-
pidemia, diabetes, and smoking; however, these
yielded minimal additive predictive value. Consid-
ering the ease of administration and the lack of need
for laboratory testing, the Diamond-Forrester model
has stood the test of time and remains the most
widely used algorithm for CAD risk assessment.
Although revascularization has been the corner-
stone for managing obstructive, symptomatic CAD
since the 1980s, parallel efforts are gradually shifting
toward optimal medical management. There is an
emerging consensus that the best candidates for
revascularization are those patients with high-risk
CAD features, rather than indiscriminately sub-
jecting the entire gamut of obstructive coronary
lesions to revascularization procedures. Although the
Diamond-Forrester model serves extremely well for
predicting those patients at risk for obstructive CAD,
the performance of this model in predicting severe
CAD is ambiguous, thus creating the need for a
prognostic tool that can accurately identify those
patients with severe CAD who are likely to derive
the greatest beneﬁt from revascularization. This
is particularly desirable in the developing world,
where appropriate allocation of limited health care
resources cannot be overemphasized.
To this point, the efforts by Yang et al. (5) are
admirable, because these investigators leveraged a
multinational CONFIRM (COronary CT Angiography
EvaluatioN For Clinical Outcomes: An InteRnational
Multicenter) registry of patients undergoing coronary
computed tomography angiography (CTA) and
developed a clinical risk prediction model for identi-
fying those patients with high-risk anatomic (HRA)
CAD (deﬁned as left main coronary artery
diameter stenosis $50%, 3-vessel disease [diameter
stenosis $70%] or 2-vessel disease involving the
proximal left anterior descending artery]). Using
clinical factors (age, sex, diabetes, hypertension,
current smoking, hyperlipidemia, family history of
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436CAD, history of peripheral vascular disease, and chest
pain symptoms), the investigators employed robust
statistical methods to derive a scoring system to
predict HRA CAD in 24,000 patients undergoing CTA
for suspected CAD. Similar to earlier models, patients
were divided into 3 risk categories: low, intermediate,
and high for pre-test probability. Overall, this risk
estimation model closely predicted the absolute level
of observed risk. The statistical metric often used
for calibration, namely the Hosmer-Lemeshow chi-
square test, demonstrated an adequate model ﬁt.
Notably, the C-statistic was particularly superior for
the newly proposed algorithm compared with the
Diamond-Forrester model in discriminating those
patients with HRA features (5). The results were
subsequently conﬁrmed in 7,000 nonoverlapping
patients in a validation cohort.
Before advocating widespread implementation
of this newly proposed model, one needs to ask
whether this adds value to the existing medical
decision-making processes. Although the study pro-
vides sophisticated and robust statistical analyses,
there is limited practical information for clinicians
who are keen on understanding the translational
implications of this model in every day practice. From
a health care delivery perspective in managing pa-
tients with suspected CAD, it is crucial to clarify the
model’s additive role in inﬂuencing choices and to
recommend standards of application in regular prac-
tice. Here are a few questions that may help facilitate
dialogue among varied stakeholders concerning
the broader utility of this decision analysis tool:
1) How many patients in this cohort had high-risk
CAD features? 2) What proportion of those features
were classiﬁed as ‘high risk’ after employing the
proposed risk model? 3) Once classiﬁed as high risk,
what is the actual likelihood for the presence of
HRA features?SEE PAGE 427Tables 1 and 5 of the paper by Yang et al. (5) in this
issue of iJACC help summarize some of this salient
information. First, it is noteworthy that only 4% to 5%
patients in the entire derivation and cohort demon-
strated features of HRA CAD (see Table 1 in Yang et al.
[5]). Second, even though being classiﬁed as “high
risk” according to the proposed model yields nearly
ﬂawless speciﬁcity and a positive likelihood ratio for
predicting HRA CAD, <1% of the study cohort
belonged to this risk category (see Table 5 in Yang
et al. [5]). Finally, once categorized as “high risk” by
using the proposed approach, merely one-fourth of
the derivation cohort exhibited features of high-risk
CAD. To complicate matters, subsequent applicationof this approach in the validation cohort further re-
duces the prevalence of HRA features by 30% in the
high-risk group.
To understand the potential translational value of
this model better, we can create an experimental
situation by applying the proposed risk prediction
score to 1,000 hypothetical patients who share base-
line characteristics with those seen in the current
CONFIRM registry. Based on the estimates provided
in Table 5 in Yang et al. (5), by using this risk pre-
diction score, only 7 of 1,000 patients will be cate-
gorized as “high risk” in which one can be persuaded
to forgo noninvasive testing and proceed directly to
invasive coronary angiography. Subsequently, only
1 of 7 of these patients will ultimately demonstrate
any features of HRA CAD. Alternatively, as Yang et al.
(5) wrote, if the goals are to consider an optimal
medical therapy trial in absence of HRA features and
avoid downstream interventions, then the notion that
further noninvasive testing should be considered in
two-thirds of the cohort deemed at intermediate risk
is debatable at best because the prevalence of high-
risk CAD in this speciﬁc group is only 5%. Given the
previously stated challenges, the overall applicability
of this seemingly promising approach is mitigated
and warrants careful scrutiny.
At this juncture, it is worth redirecting attention to
pursue a root cause analysis of the discrepancies
between strong statistical signiﬁcance and weak
clinical relevance observed in this study. The ﬁrst
striking element is the heterogeneous population
mix. One-fourth of the CONFIRM registry participants
are asymptomatic, which lowers overall applicability,
because cardiologists are primarily confronted with
symptomatic patients. For example, a 70-year
asymptomatic man who has a family history of coro-
nary heart disease, is a smoker, is diabetic with mild
dyslipidemia, and has well-controlled hypertension
will be classiﬁed as high risk by the proposed risk
prediction model. Supported by evidence and guide-
lines, invasive angiography or revascularization
would rarely be considered as a ﬁrst choice in
asymptomatic patients.
The second factor that may explain the limited
clinical signiﬁcance of this risk prediction model is
the relatively low value assigned to the presence and
severity of classic angina symptoms, which to date
remain the central factors inﬂuencing management
decisions. In the derivation of the risk prediction
model, similar weight is given to typical angina and to
any of the following conventional risk factors for
cardiovascular disease: diabetes, smoking, family
history of CHD. A 66-year-old woman with history of
smoking, diabetes and known peripheral vascular
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437disease who is presenting with typical anginal pain
will be at best considered as having intermediate risk
by the current algorithm. This is certainly contrary to
conventional wisdom. This reminds me of a question
posed by George Diamond (6) a few years ago, “Do
symptoms matter?” While explaining the signiﬁcant
discrepancies between HRA CAD lesions and clinical
symptoms noted in an earlier study from the same
cohort, Diamond (6) eloquently attributed the differ-
ences to the following reasons: the inability of a self-
administered patient questionnaire to capture the
true essence of symptom severity; the inclusion in the
CONFIRM registry of features such as jaw pain and
arm pain in the deﬁnition of typical angina that would
be considered atypical using the traditional algo-
rithm; and the absence of patients in the current
cohort undergoing coronary CTA and who presented
with extreme manifestations of ischemia who would
have likely been referred for invasive angiography,
thereby resulting in preferential referral bias from
patients who are at the lower end on the severity
spectrum of ischemia.
These discussions have led me to wonder ‘what if’ a
risk prediction model was developed using an appro-
priately high-risk cohort that excluded asymptomatic
patients as well as using additional variables not
accounted for in the current study? In a recent study of
551 patients presenting with typical chest pain who
proceeded to invasive coronary angiography, Chen
et al. (7) found that age, male sex, aortic valve calciﬁ-
cation on echocardiography, an abnormal electrocar-
diogram, diabetes, hyperlipidemia, and dyslipidemia
independently predicted CAD severity. Furthermore,
when these variables were used to develop a risk pre-
diction scoring system, consistent with the currentstudy, the system performed well ‘statistically’ on
calibration metrics and signiﬁcantly discriminated
those patients with and without severe CAD compared
with the Diamond-Forrester model. However, the re-
sults of Chen et al. (7) compared with the current study
by Yang et al. (5) were distinctly different where it
mattered the most. First, a signiﬁcant proportion of
patients in the study by Chen et al. (7) was identiﬁed as
high risk on the scoring metrics (57% vs. 1%). Second,
the likelihood that these patients had high-risk CAD
features was signiﬁcantly greater (90% vs. 17% to
24%). These consequential disparities noted could
have been avoided if the ‘right’ question had been
asked in the ‘right’ population.
In summary, considering the evolving landscape of
CAD management, the broad scope of application and
the grave consequences of misclassiﬁcation under-
score the continued quest to reﬁne existing risk
assessment tools. The current study and similar ef-
forts are the ﬁrst steps toward the ultimate goal. At
the same time, certain key considerations, high-
lighted earlier, are worth careful scrutiny before
embarking on similar subsequent endeavors. Never-
theless, the results from Yang et al. (5) provide the
necessary momentum that must carry forward, with
cautious optimism and mindful awareness of the
subtle intricacies embedded in the “art of science”
related to medical decision making.
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